UK Government Invests £100 Million in AI to Counter Biological Threats

The United Kingdom is investing £100 million in a new laboratory that will use artificial intelligence to detect and tackle biological threats faster. The British government announced the plan on 24 October.

The new AI Biosecurity Lab will help identify pathogens and support the development of vaccines and treatments. Biology is a critical national security issue—especially at a time when malicious actors have more opportunities than ever.

OpenAI, Anthropic and Google DeepMind are also involved. According to the British government’s official announcement, OpenAI and Anthropic will together provide up to £200 million in AI services, computing power and support.

Biosecurity focuses on preventing, detecting and tackling threats posed by viruses, bacteria and other pathogens.

These threats can come from natural infectious disease outbreaks, laboratory accidents or deliberate misuse.

The British government plans to use advanced AI systems to better understand these risks.

AI can analyse vast amounts of biological and medical data, helping researchers uncover patterns that traditional research might take longer to reveal.

The new laboratory will therefore have two main tasks.

First, it will help identify emerging biological threats earlier.

Second, the government aims to speed up the development of medical countermeasures, including vaccines, medicines and other treatments.

For now, the announcement sets out plans to establish the lab and defines its goals. The government has yet to show that the initiative will actually speed up vaccine development or prevent future outbreaks.

Partnerships with major AI companies are central to the plan.

OpenAI says it will provide £100 million worth of computing power, model credits and access to advanced AI models, including through its Rosalind Biodefense programme.

Anthropic will provide up to £100 million in model credits, access to AI systems and technical support, according to the British government.

These sums are not straightforward cash investments in the laboratory. Most of the contribution takes the form of access to technology and services.

Google DeepMind will collaborate on research and explore making its AI models available for specialised applications.

UK-based Basecamp Research will also contribute biological AI technology and scientific expertise.

Together, these organisations bring different kinds of expertise. Tech companies provide powerful AI systems, while biomedical researchers identify which data and methods are scientifically relevant.

AI Wereld previously covered Anthropic’s plans to use AI to develop its own medicines.

The new British initiative has a broader focus: biosecurity and preparedness for health threats.

The investment has another purpose.

Ever more powerful AI models could help researchers, but they may also lower the barrier for people seeking to misuse dangerous biological knowledge.

The British government therefore wants to investigate the risks these systems could pose.

That does not mean AI is currently causing pandemics on its own, or that every powerful language model can carry out dangerous biological experiments.

The concern is about potential uses and risks that experts want to identify early.

That is why the UK is establishing a specialist organisation to bring AI research and biosecurity together.

The laboratory will work with British public health authorities, defence researchers and agencies responsible for medicines safety.

According to the government, the AI Biosecurity Lab will operate as an independent, not-for-profit organisation.

The laboratory is part of a broader package of UK investment in AI.

According to a separate government announcement, £165 million will go towards a national programme addressing biological threats. Of that amount, £100 million is earmarked for the AI Biosecurity Lab and £65 million for measures including biological surveillance and medical countermeasures.

The government has also announced additional investment in securing AI systems and protecting digital infrastructure.

The UK is seeking to achieve two goals at once: reap the benefits of scientific progress while ensuring new technology does not amplify existing security risks.

The development is worth watching in Europe, where the UK is treating AI not just as an economic tool, but as part of its national health and security infrastructure.

Ultimately, the laboratory’s success will depend on what it delivers. Faster analysis is valuable, but medicines and vaccines still need to undergo scientific testing.

Above all, the announcement shows how AI companies are becoming increasingly involved in research and infrastructure once handled largely by universities, pharmaceutical firms and government agencies.